UW26001 Phase I/II Study on the Safety, Tolerability, and Preliminary Efficacy of ASTX727 (Decitabine/Cedazuridine) and Retifanlimab-dlwr in Patients With Advanced Merkel Cell Carcinoma Who Have Progressed on Anti-PD-(L)1 Inhibitor

The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are:
* Can the combination shrink cancer and lower the chance of the cancer growing or spreading?
* Is the combination better than standard of care for Merkel cell cancer?
Participants will:
* Take oral ASTX727 and retifanlimab through a vein in the arm for about 2 years.
* Visit the clinic once every 2 weeks for checkups and tests

开始日期2026-05-01

申办/合作机构

University of Wisconsin-Madison

NCT07468136

/ Not yet recruiting临床1/2期IIT

Phase I/IIa Trial of Retifanlimab and Difluoromethylornithine (DFMO) in Patients With Progressive High-Grade Glioma

This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. DFMO is in a class of medications called ornithine decarboxylase (ODC) inhibitors. It works by blocking the action of a substance that signals tumor cells to multiply. This helps stop or slow the spread of tumor cells. Giving retifanlimab with or without DFMO mat be safe, tolerable and/or effective in treating patients with progressive high grade glioma.

开始日期2026-04-24

申办/合作机构

Mayo Clinic

NCT07425054

/ Not yet recruiting临床2期IIT

ctHPVDNA Adapted ChemoRadiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer (CHART-AC)

This study is for people who have anal cancer and have not yet had treatment. The regular treatment for people who have anal cancer is chemoradiation therapy (CRT). CRT is when chemotherapy and radiation therapy are given at the same time. Studies show that CRT works well to treat anal cancer and prevents many people from needing surgery which may require a colostomy bag. Doctors know that CRT is an effective way to treat anal cancer. But, they are doing studies to find out how much dose of radiation and chemotherapy should be given during the CRT. Higher doses of chemotherapy and radiation could increase the risk of side effects, but lowering the dose of chemoradiation has the risk of not being as effective to treat the cancer. One way to predict whether participants need higher or lower doses of radiation therapy is to do a blood test called ctDNA (circulating tumor DNA) to test for the presence of human papillomavirus (HPV). This test is done at certain times while participants are getting CRT. This has been shown to be a marker for the presence of anal cancer.
In this study, doctors will tailor lower versus higher doses of CRT based on the tumor response that is measured by ctDNA. The purpose of this study is to see if customizing the dose of chemoradiation based on the amount of ctDNA will increase survival in participants with anal cancer and/or decrease the risk of side effects. Some participants in this study whose cancer does not respond as well to the CRT may have the opportunity to receive a drug called Retifanlimab that stimulates the body's immune system. Retifanlimab is approved by the Federal Drug Administration (FDA) for treating anal cancer that is recurrent or metastatic since there is proven benefit in these situations.

开始日期2026-03-01

申办/合作机构

The Case Comprehensive Cancer Center

[+1]

100 项与瑞弗利单抗相关的临床结果

登录后查看更多信息

100 项与瑞弗利单抗相关的转化医学

登录后查看更多信息

100 项与瑞弗利单抗相关的专利（医药）

登录后查看更多信息

项与瑞弗利单抗相关的文献（医药）

2026-03-16·Future Oncology

Avelumab real-world use in advanced Merkel cell carcinoma: a systematic review and non-comparative meta-analysis

Review

作者: Moradian, Hoora ; Freitag, Andreas ; Rutherford, Megan ; Kearney, Mairead ; Kwon, Christina ; Lan, Zhiyi

AIM:

Programmed death (ligand) 1 inhibitors (e.g., avelumab, pembrolizumab, and retifanlimab) are first-line treatment options for patients with locally advanced or metastatic Merkel cell carcinoma (MCC). In the absence of comparative and randomized trials, we aimed to systematically identify and synthesize real-world evidence (RWE) on the effectiveness and safety of immunotherapies in patients with advanced MCC.

METHODS & MATERIALS:

MEDLINE and Embase searches were conducted for observational RWE studies in locally advanced or metastatic MCC from January 2017 to December 2023. Avelumab was the only immunotherapy with sufficient data for analysis. Landmark 12-month overall survival (OS) and progression-free survival (PFS) were assessed by meta-analysis.

RESULTS:

Screening of 1731 records identified 37 publications eligible for inclusion (16 unique studies), of which eight were included in the meta-analysis. In line with results from the JAVELIN Merkel 200 trial, pooled 12-month OS rates of 77.7% in stage III and 63.0% in stage IV MCC and 12-month PFS rates of 53.3% and 39.3%, respectively, were estimated. Although safety data were insufficient for meta-analysis, two retrospective studies reported lower adverse event rates than JAVELIN Merkel 200.

CONCLUSIONS:

The results of this study support broader use of avelumab in advanced MCC.

2026-03-01·International Journal of Clinical Oncology

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

作者: Matsumura, Noriomi

2026-02-01·Cancer research communications

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

Article

作者: Adamow, Mathew ; Reed, Damon R. ; D’Angelo, Sandra P. ; Tap, William D. ; Movva, Sujana ; Wong, Phillip ; Avutu, Viswatej ; Desir, Rhoena ; Biniakewitz, Matthew ; Keohan, Mary Louise ; Lefkowitz, Robert A. ; Singer, Samuel ; Chi, Ping ; Koff, Andrew ; Erinjeri, Joseph P. ; Maki, Robert G. ; Kelly, Ciara M. ; Antonescu, Cristina R. ; Seffar, Evan ; Bradic, Martina ; Lee, Jasme ; Shen, Ronglai ; Chan, Jason E. ; Rosenbaum, Evan ; Gularte-Mérida, Rodrigo ; Dickson, Mark A. ; Qin, Li-Xuan ; Banks, Lauren B. ; Gounder, Mrinal M. ; Panageas, Katherine S.

Abstract:

Purpose::

The CDK4/6 inhibitor palbociclib delays progression in patients with advanced dedifferentiated liposarcoma (DDLPS). In carcinoma models, CDK4/6 and PD-1 inhibition induce intratumoral inflammation and synergistic activity. Comprehensive assessment of tumor and host dynamics is needed to understand response and resistance to this combination.

Patients and Methods::

We performed a phase 2 study of palbociclib and the PD-1 inhibitor retifanlimab in advanced DDLPS. Palbociclib was administered 2 weeks prior to retifanlimab. Tumor biopsies were analyzed by single-cell RNA sequencing (scRNA-seq), and peripheral blood by high-parameter flow cytometry. Analyses focused on cell cycle, senescence, and immune-related changes.

Results::

Twelve patients were treated before the study was halted because of a 42% immune-related toxicity rate. The overall response rate was 8.3%, and the disease control rate was 75%. Median progression-free and overall survival rates were 7.1 and 26.8 months, respectively. Nine patients had at least one tumor biopsy analyzed; three had paired. Ten patients had paired blood samples analyzed. Following treatment, tumor cells demonstrated decreased cycling and increased cell-cycle checkpoint activity. Transcriptional scores for senescence increased in cancer cells, as did the proportion of intratumoral T and B cells. A cluster of cells emerged with upregulated cell-cycle genes and downregulated HLA class I, suggesting innate or acquired resistance to treatment. In blood, a subset of CD4+ T cells decreased, whereas expression of LAG-3, ICOS, and CD38 increased in select subsets.

Conclusions::

A palbociclib lead-in prior to retifanlimab had a high rate of immune-related toxicities. Correlative analyses identified changes in tumor and immune cells attributable to treatment. A study of concurrent dosing of the combination is ongoing.

Significance::

In this phase 2 study of palbociclib and retifanlimab, treatment led to immune-related adverse events, halting enrollment. scRNA-seq and flow cytometry revealed cell-cycle suppression, senescence, and T-cell changes. These findings highlight the rationale for this combination and the need for safer dosing strategies in larger cohorts.

223

项与瑞弗利单抗相关的新闻（医药）

2026-05-04

·EndPoints

Celcuity's breast cancer win; Odyssey plans $205M IPO

Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year, Celcuity reported that the drug staved off cancer progression in patients without PIK3CA mutations, and the company is awaiting a July FDA approval in that setting. The company is studying its drug as a second-line treatment for patients with HR-positive, HER2-negative breast cancer. The Minneapolis-based company said Friday that gedatolisib plus two other drugs —fulvestrant and Pfizer’s Ibrance — beat a combination of Novartis’ Piqray and fulvestrant, meeting the study’s primary endpoint. Another secondary analysis also showed that gedatolisib plus fulvestrant — without Ibrance — also beat Piqray plus fulvestrant. Celcuity is now headed to the FDA to ask for approval of gedatolisib in PIK3CA mutant patients as well. Unlike Piqray or Roche’s Itovebi, which are only approved for patients with a PIK3CA mutation, gedatolisib is meant to hit multiple parts of the key cancer pathway. As a result, Celcuity is aiming for a broad approval encompassing both wildtype and mutant forms of the cancer. — Lei Lei Wu 🚀 Odyssey charts $205M IPO: The biotech plans to raise that amount in net proceeds from its proposed Nasdaq listing as $ODTX . The autoimmune and inflammatory disease startup previously attempted an IPO in 2025 but pulled back and went with a Series D instead. Now, it seeks to sell 13.24 million shares at $16 to $18 apiece after Kailera Therapeutics, Avalyn Pharma, Seaport Therapeutics and Hemab Therapeutics opened the IPO window heading into the summer. — Kyle LaHucik 💸 Gene therapy biotech gets $43M: Philadelphia startup Latus Bio has extended its 2024 Series A to a total of $97 million as it looks to begin two clinical trials this year. The company will test AAV-based gene therapies for Huntington’s disease and CLN2 disease. Its backers include 8VC, DCVC Bio and others. — Kyle LaHucik MacroGenics expands royalty deal: The biotech will get $60 million upfront and up to $20 million more based on a 2026 sales milestone for Zynyz. Sagard Healthcare Partners and MacroGenics formed the initial deal around the Incyte-commercialized PD-1 inhibitor last year. — Kyle LaHucik Mirum scores Phase 2b win for liver drug: The biotech said volixibat hit its primary endpoint in the trial, which enrolled patients with a rare liver condition called primary sclerosing cholangitis. Individuals with the chronic disease have inflammation in the bile ducts, leading to liver damage, according to the Mayo Clinic. Volixibat is designed to treat a common itching symptom (cholestatic pruritus) that comes with the disease. Mirum plans an FDA submission in the second half of 2026. — Max Gelman Indivior begins $175M share repurchase: The move comes after the company said last week that it would punt on Phase 3 studies for a program called INDV-6001, and that a Phase 2 trial for INDV-2000 in opioid use disorder had failed. — Max Gelman

临床2期上市批准临床3期

2026-05-04

·BioSpace

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it entered into an expanded royalty purchase agreement with Sagard in exchange for a capped royalty interest on future global net sales of ZYNYZ ® (retifanlimab-dlwr). MacroGenics and Sagard entered into the initial ZYNYZ royalty purchase agreement in June 2025. ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte Corporation pursuant to an exclusive global collaboration and license agreement in October 2017. MacroGenics retains its other economic interests related to ZYNYZ, including future potential development, regulatory and commercial milestones. Under the terms of the amended royalty purchase agreement, MacroGenics receives a $60 million upfront payment from Sagard and is eligible to receive an additional 2026 sales-based milestone of up to $20 million for the sale of its royalty rights on global net sales of ZYNYZ. All royalty rights will revert back to MacroGenics once Sagard has received total payments of either 1.7x its investment by September 30, 2032, or 2.0x its investment at any time thereafter. Additional information regarding the expanded royalty purchase agreement is provided in a Current Report on Form 8-K filed by MacroGenics with the U.S. Securities and Exchange Commission. About ZYNYZ Zynyz ® (retifanlimab) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) in the U.S, Europe and Japan and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S. Zynyz is also indicated as monotherapy for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S., EU, Canada and Switzerland. Zynyz is marketed by Incyte in the U.S. Zynyz is a registered trademark of Incyte. About  MacroGenics, Inc. MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at . MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. About Sagard Sagard is a global multi-strategy alternative asset management firm with over $45 billion USD i in assets under management, 190+ portfolio companies, and 540 professionals. Sagard invests in venture capital, private equity, private credit, and real estate. The firm delivers flexible capital, an entrepreneurial culture, and a global network of investors, commercial partners, advisors, and value creation experts. The firm has offices in Canada, the United States, Europe, Asia and the Middle East. For more information, visit or follow Sagard on LinkedIn. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of clinical updates and safety and efficacy data for the Company’s ongoing clinical trials and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, including MacroGenics’ ability to execute on the Company’s key strategic priorities for 2025 and 2026, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, lorigerlimab, ZYNYZ, or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to TZIELD, lorigerlimab, ZYNYZ, or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates, including timing and results of efficacy and safety data with respect to product candidates in ongoing clinical trials; the Company’s ability to provide manufacturing services to its customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of its product candidates; expectations of expanding ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; the Company’s ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. i As of December 31, 2025. Pro-forma for the Unigestion transaction which closed in April 2026. Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com

引进/卖出上市批准

2026-05-03

·网易号

上海交通大学附属胸科医院肿瘤中心临床试验汇总（2026年5月）

人文关怀临床试验汇总•早中期非小细胞肺癌（6）1. 在根治性同步放化疗后稳定的III期NSCLC中评价Durvalumab作为巩固治疗的III期、双盲、随机对照研究2. 在根治性放化疗后稳定的EGFR突变阳性III期NSCLC中评价奥希替尼作为巩固治疗的III期、双盲、随机对照研究（LAURA）3. 在Ib-IIIA期ALK阳性NSCLC完整手术切除后阿来替尼和辅助化疗对照的III期研究4. 在完全切除的II-IIIA期和IIIB期非小细胞肺癌患者中评价卡那奴单抗作为辅助治疗与安慰剂对照的III期研究（诺华CACZ885T2301）5. 在可切除IIA-IIIB期NSCLC中评估纳武利尤单抗或安慰剂联合含铂化疗的双盲、随机的III期研究6. 在可切除IIIA/IIIB（N2）期NSCLC中评估特瑞普利或安慰剂联合含铂化疗的双盲、随机的III期研究（君实JS001-029）7. 特瑞普利单抗联合含铂双药化疗用于可手术II-III期非小细胞肺癌受试者的随机、双盲、安慰剂对照、多中心III期临床研究•晚期驱动基因阳性非小细胞肺癌（24）8. 达克替尼治疗EGFR敏感突变的非小细胞肺癌脑转移的II期研究9. 阿法替尼治疗EGFR敏感突变的鳞癌的II期研究10. 一项在 EGFR突变局部晚期或转移性非小细胞肺癌患者中评价Amivantamab和 Lazertinib联合给药对比奥希替尼或Lazertinib单药一线治疗的III期、随机研究11. 一项在 EGFR 20号外显子插入突变的局部晚期或转移性非小细胞肺癌患者中比较 Amivantamab和卡铂-培美曲塞的联合治疗与卡铂-培美曲塞治疗的随机化、开放性、 III 期研究12. 谷美替尼联合奥希替尼治疗EGFR-TKI耐药的晚期NSCLC的IB/II期研究（已结束）13. 评估金妥昔单抗联合阿美替尼治疗EGFR突变IV期NSCLC患者的IB期及IB期扩展研究（已结束）14. 评估信迪利单抗和IBI305联合培美曲塞／顺铂用于酪氨酸激酶抑制剂治疗失败的 EGFR突变晚期非鳞非小细胞肺癌的有效性和安全性的开放III期临床试验15. 在NSCLC中JNJ-73841937单药或者JNJ-61186372联合治疗的安全性和药代动力学的的I/IB期开放性研究（1001）（已结束）16. 评估SHR-1701在晚期恶性实体瘤的I期临床研究（已结束）17. 评价XZP-3621治疗ALK阳性晚期非小细胞肺癌患者剂量递增和剂量扩展的I期研究（已结束）18. 在克唑替尼进展后的ALK阳性NSCLC患者中比较Brigatinib与Alectinib的III期随机研究19. 评价TQ-B3101治疗ROS1阳性晚期非小细胞肺癌的II期研究（已结束）20. Entrectinib治疗NTRK1/2/3、ROS1融合的晚期实体瘤的全球II期篮式研究21. 评价TQ-B3101治疗晚期非小细胞肺癌的II期研究（已结束）22. SIM1803-1A 治疗NTRK1/2/3、ROS1、ALK融合的晚期实体瘤的I期（已结束）23. 吡咯替尼联合沙利度胺治疗HER2突变的晚期NSCLC24. 评价ABBV-399治疗经治的c-MET阳性晚期非小细胞肺癌的II期研究25. 评估口服谷美替尼在c-MET改变的NSCLC患者中Ib/II期研究（已结束）26. 一项在携带ALK、ROS1或NTRK1-3重排的晚期实体瘤患者中评价TPX-0005的安全性、耐受性、药代动力学和抗肿瘤活性的I/II期、开放性、多中心、首次人体研究（TRIDENT-1）27. 评估D-1553在晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学和有效性的I期、开放研究28. 一项评估阿法替尼治疗NRG1融合的局部晚期/转移性非小细胞肺癌疗效的开放标签、单臂临床研究29. 评价赛沃替尼治疗MET外显子14突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者的有效性、安全性和耐受性的多中心、开放的IIIb期确证性临床研究30. 评价赛沃替尼联合奥希替尼对比培美曲塞联合铂类治疗经EGFR抑制剂治疗失败伴MET扩增的局部晚期或转移性NSCLC患者的有效性和安全性的多中心、随机、对照、开放的III期临床研究31. 一项评价FWD1509 MsOH在晚期非小细胞肺癌患者中的安全性耐受性药代动力学和抗肿瘤活性的开放性Ia期研究32.一项评估帕博利珠单抗联合仑伐替尼用于TKI耐药的EGFR突变且PD-L1阳性的非小细胞肺癌病人的开放性单臂研究33. 一项评估H002在表皮生长因子受体突变阳性的局部晚期或转移性非小细胞肺癌患者中的安全性、耐受性、药代动力学和初步抗肿瘤活性的开放性、剂量递增和扩展的I/IIa期临床研究34. 一项在携带RET突变或融合的不可切除、局部晚期或转移性实体瘤成人患者中研究APS03118的安全性、耐受性、药代动力学和初步疗效的I期研究•晚期驱动基因阴性非小细胞肺癌（3）35. 比较INCMGA00012+含铂化疗与含铂化疗一线治疗IV期鳞癌和非鳞癌的III期研究（已结束）36. 在晚期实体瘤患者中评估抗TIGHT单抗BGB-A1217/联合BGB-A317的I/IB期研究37. 多中心、开放和平行对照比较GB226工艺变更前后在晚期NSCLC中的药代动力学对比研究•小细胞肺癌（3）38.同步放化疗后稳定的局限期小细胞肺癌使用Durvalumab或Durvalumab+Tremelimumab作为巩固治疗的III期试验（ADRIATIC）39. 一项在既往未接受过治疗的广泛期小细胞肺癌患者中评估阿替利珠单抗加卡铂和依托泊苷联合或不联合Tiragolumab治疗的Ⅲ期、随机、双盲、安慰剂对照研究（YO42373）40. 临床试验招募丨重组全人抗PD-L1单克隆抗体注射液或安慰剂联合卡铂和依托泊苷一线治疗广泛期SCLC的的III期临床研究•胸腺癌（1）41. 评价Atezolizumab治疗经治晚期胸腺癌的II期研究上海交通大学附属胸科医院肺部肿瘤临床医学中心上海交通大学附属胸科医院肿瘤科（上海市肺部肿瘤临床医学中心），成立于2006年，在国内率先建立肺癌多学科诊治团队，开展精准医学指导下的个体化综合治疗。科室承担国家科技重大专项-重大新药创制课题，国家重点研发计划“基于组学特征的肺癌免疫治疗疗效预测指标的构建和验证”、科技部国家国际合作专项“中瑞合作肺癌临床医学中心肺癌诊治关键技术转化医学研究”，国家自然科学基金13项，省部级以上课题34项。承担50余项国际多中心临床试验，其中包括三项国家1.1类新药临床研究。2009年，肿瘤科成功完成中国大陆第一例达芬奇机器人辅助下的肺癌肺叶切除术、胸腺瘤切除术等。目前肿瘤科达芬奇手术保持全国第一。施行了国内第一例四维磁导航引导下的肺癌经皮氩氦刀消融术，多次实施了射频消融治疗、氩氦冷冻消融微创治疗等。目前科室有上海市领军人才、上海市优秀学科带头人1名；上海市优秀技术带头人1名；上海市青年拔尖人才2人；浦江人才2人；1人获上海市银蛇奖提名；3人获上海市人才发展基金资助；2人获上海市科委“扬帆”基金资助；1人获得上海交通大学九龙医学奖。首席专家：廖美琳；周允中学科学术带头人：陆舜科室主任：李子明行政副主任：陈智伟，成兴华肿瘤外科：19名医生，肿瘤内科：20名医生主任及副主任：14；主治医师：18；住院医师：5；实验室助理研究员：2床位：147张发展历史“上海市肺部肿瘤临床医学中心”在上海市卫生局、上海市胸科医院领导关心支持下于2002年2月5日纳入上海市临床医学中心第二批的建设项目，同年5月8日正式在胸科医院成立，2006年4月随新病房楼的落成而投入正常使用。通过贯彻肺癌的多学科规范化诊治，临床医学中心救治了大量来自全国各地的复杂疑难重症患者；承担全市乃至全国的干部保健工作,并通过远程会诊及合作办医,不断扩大中心的影响力和辐射面。临床中心的发展经历了3个阶段：第一阶段：启动阶段，2002年以前老一辈专家们进行了多学科诊治的尝试，完成了国家八五攻关课题、上海市领先学科（肺部肿瘤学）的研究，取得了丰硕的成果。第二阶段：正式成立，2002年5月上海市肺部肿瘤临床医学中心正式成立，当时拥有内科十病区、外科八病区部分、特需外科、特需内科，总床位数约90张。试运行期间，内外科通力协作，发挥多学科诊治的特色，顺利完成了上海市领先学科课题的研究，并通过验收，获得上海市医学科技三等奖。第三阶段：中心病房正式运作，2006年4月1日临床中心正式运转，规模继续扩大。目前临床中心由中心办公室、中心门诊、中心病房组成；临床中心病房由3个病区构成，拥有床位数123张，其中普通床位98张（层流室床位3张），干部病床25张。目前临床中心拥有电视胸腔镜、电视纵隔镜、支气管腔内超声仪、百万级层流设备、血细胞分离机以及各种监护设备，能够满足肺部肿瘤多学科诊断、治疗、临床研究的需求。肺部肿瘤临床中心的就医病员来自全国各地，市内病人占60%，外地病人占40%，海外病员来自香港、澳门、台湾及世界各地。建设中国肺癌精准诊疗“新模式，新标准”药明康德生命化学研究奖药明康德生命化学研究奖是经国家科学技术奖励工作办公室批准，药明康德新药开发有限公司设立的奖项，旨在奖励中国医药研发领域在科研创新、成果推广及高新技术产业化等方面取得重大成果的优秀中青年科技人才。2021年第十五届“药明康德生命化学研究奖”在“云端”揭晓，陆舜教授凭借肺癌精准治疗策略及新药创新体系的建立获得科技成果转化奖。● 长三角肺癌基金 ●●●●Yangtze River Delta Lung Cancer Fund●●●长三角肺癌基金长三角肺癌心路历程回顾心路历程1:2019.12 长三角肺癌协作组成立心路历程2:2020.04 长三角肺癌协作组临床试验招募启动心路历程3:2020.07 长三角肺癌协作组青年医师巡讲团成立心路历程4:2021.01 长三角肺癌协作组青年博士团队成立心路历程5:2021.03 江苏省基层肺癌协作组成立心路历程6:2021.04 长三角肺癌基因多平台检测实验室揭牌心路历程7:2021.05 浙江省基层肺癌协作组成立心路历程8:2021.07 长三角肺癌多中心研究样本库建立心路历程9：2024.12 浙江省基层罕见肿瘤协作组成立长三角肺癌沪浙苏赣临床试验四驱动一体化建设长三角肺癌沪浙苏赣临床试验四驱动一体化建设添加群管理员（微信号：hangjiajia2020）进群交流长三角肺毛玻璃结节病友交流群，长三角肺癌EGFR病友交流群，长三角肺癌ALK病友交流群，长三角肺癌ROS1病友交流群，长三角肺癌RET病友交流群，长三角肺癌MET病友交流群，长三角肺癌KRAS病友交流群，长三角肺癌BRAF病友交流群，长三角肺癌HER2病友交流群，长三角肺癌FGFR病友交流群，长三角小细胞肺癌病友交流群，长三角肺癌免疫治疗病友交流群，长三角食管癌病友交流群，长三角胸腺瘤病友交流群，长三角间皮瘤病友交流群，长三角头颈部肿瘤病友交流群，长三角胃癌病友交流群，长三角结直肠癌病友交流群，长三角肝胆胰肿瘤病友交流群，长三角乳腺癌病友交流群，长三角泌尿系统肿瘤病友交流群，长三角妇科肿瘤病友交流群，长三角软组织肿瘤病友交流群，长三角黑色素瘤病友交流群。

100 项与瑞弗利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11827	-	-	DB15766

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
梅克尔细胞癌	美国	Incyte Corp.	2026-03-30
肛管鳞状细胞癌	美国	Incyte Corp.	2025-05-15
转移性Merkel细胞癌	美国	Incyte Corp.	2023-03-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肛门鳞状细胞癌	申请上市	欧盟	Incyte Biosciences Distribution BV	2026-01-29
非小细胞肺癌	申请上市	美国	Incyte Corp.	-
子宫内膜癌	临床3期	中国	再鼎医药（上海）有限公司	2021-09-20
转移性非小细胞肺癌	临床3期	中国	Incyte Corp.	2020-09-18
转移性非小细胞肺癌	临床3期	中国	再鼎医药（上海）有限公司	2020-09-18
转移性非鳞状非小细胞肺癌	临床3期	美国	Incyte Corp.	2020-09-11
转移性非鳞状非小细胞肺癌	临床3期	中国	Incyte Corp.	2020-09-11
转移性非鳞状非小细胞肺癌	临床3期	巴西	Incyte Corp.	2020-09-11
转移性非鳞状非小细胞肺癌	临床3期	保加利亚	Incyte Corp.	2020-09-11
转移性非鳞状非小细胞肺癌	临床3期	捷克	Incyte Corp.	2020-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05287113 (CTgov)	临床2期	头颈部鳞状细胞癌 \| PD-L1阳性实体瘤	176	Retifanlimab (Retifanlimab)	夢構窪壓範積壓醖廠窪(襯製淵網構觸積餘網糧) = 積選淵壓鑰製製醖淵願簾鹽選艱網齋製鏇糧夢 (積膚選餘餘壓製窪醖膚, 構繭襯築窪壓淵觸鹽廠 ~ 鏇積願顧齋廠淵齋築製) 更多	-	2026-03-27
				Retifanlimab (Retifanlimab Plus INCAGN02385)	夢構窪壓範積壓醖廠窪(襯製淵網構觸積餘網糧) = 糧繭鬱選獵餘積獵糧醖簾鹽選艱網齋製鏇糧夢 (積膚選餘餘壓製窪醖膚, 觸齋蓋簾遞簾觸艱鹽選 ~ 夢網製壓鏇簾觸夢糧鹹) 更多
NCT04472429 (POD1UM-303, ESMO_IO2025)	临床3期	肛门鳞状细胞癌一线	308	Retifanlimab + carboplatin-paclitaxel	憲鏇簾餘糧餘築壓蓋窪(憲構憲鬱製鹹願衊顧憲) = 鹹夢築齋鬱餘襯齋膚夢獵觸築鏇網鏇製顧觸襯 (醖繭襯範廠衊遞構製簾 ) 更多	积极	2025-11-12
				Placebo + carboplatin-paclitaxel	憲鏇簾餘糧餘築壓蓋窪(憲構憲鬱製鹹願衊顧憲) = 觸蓋蓋製艱夢網壓鏇淵獵觸築鏇網鏇製顧觸襯 (醖繭襯範廠衊遞構製簾 ) 更多
EUCTR2021-005775-39-BE (ESMO2025)	临床2期	PD-L1+	176	Retifanlimab (RETI)	構遞選餘顧壓鏇顧襯獵(範繭積積夢鏇鏇醖願積) = 艱獵鹽廠獵簾觸觸網蓋選簾觸夢餘鬱壓淵醖範 (鹽鏇願鏇餘簾齋遞餘蓋, 3.5 ~ 9.7) 更多	不佳	2025-10-17
				Retifanlimab + Tuparstobart (doublet tx)	構遞選餘顧壓鏇顧襯獵(範繭積積夢鏇鏇醖願積) = 壓遞餘鏇糧觸齋壓鑰選選簾觸夢餘鬱壓淵醖範 (鹽鏇願鏇餘簾齋遞餘蓋, 3.7 ~ 7.6) 更多
NCT04205812 (POD1UM-304, Pubmed) 人工标引	临床3期	非小细胞肺癌一线	583	Retifanlimab + chemotherapy	鹽製窪願願夢鑰廠齋艱(壓窪網齋獵壓鏇製壓壓) = 積範齋衊廠網遞簾糧鑰夢蓋繭壓鹹築艱齋觸鹽 (壓繭願蓋簾糧糧齋醖積, 16.2 ~ 21.0) 更多	积极	2025-09-19
				Placebo + chemotherapy	鹽製窪願願夢鑰廠齋艱(壓窪網齋獵壓鏇製壓壓) = 願壓艱糧繭醖蓋築襯構夢蓋繭壓鹹築艱齋觸鹽 (壓繭願蓋簾糧糧齋醖積, 11.0 ~ 16.7) 更多
NCT03532295 (CTIM-23, CTgov)	临床2期	多形性胶质母细胞瘤 \| 胶质母细胞瘤 \| 复发性胶质母细胞瘤	51	Radiation therapy+Bevacizumab+Retifanlimab (Regimen A: Retifanlimab+RT+bevacizumab)	鑰構廠網顧鹽積範鏇壓 = 糧鹽壓積艱夢範製衊製積膚襯蓋遞膚窪襯鏇選 (顧鑰選製範構繭夢繭獵, 襯醖築鹹淵遞蓋鑰壓壓 ~ 窪鏇顧網範蓋壓願築築) 更多	-	2025-08-07
				Radiation therapy+Bevacizumab+Epacadostat+Retifanlimab (Regimen B: Retifanlimab+RT+bevacizumab+epacadostat)	鑰構廠網顧鹽積範鏇壓 = 憲顧醖餘餘網製艱構獵積膚襯蓋遞膚窪襯鏇選 (顧鑰選製範構繭夢繭獵, 鬱網製餘餘鬱憲醖遞遞 ~ 醖夢餘積艱繭夢簾繭選) 更多
NCT04116073 (CTgov)	临床2期	不能切除性胰腺癌	25	PD-1 antibody+INCMGA00012	願醖蓋獵簾壓網窪憲鬱 = 遞艱膚鑰積簾糧糧繭觸憲繭選顧鏇鏇醖製鹽鬱 (鏇築淵廠鹽鹹蓋製構觸, 製壓憲鑰積艱壓窪簾獵 ~ 糧餘蓋鏇積觸鏇獵構淵) 更多	-	2025-07-29
NCT05239182 (RiLEY, CTgov)	临床2期	胰腺腺癌 \| 胰腺导管腺癌 \| 晚期胰腺腺癌	7	9-ING-41+Abraxane+Gemcitabine+Retifanlimab	積壓衊鏇壓簾選簾築壓 = 餘築顧鑰顧獵窪遞蓋淵憲醖襯網艱網襯衊廠顧 (網襯艱壓積蓋遞夢廠衊, 願願窪齋廠觸壓襯醖糧 ~ 遞選積膚願淵製餘糧鏇) 更多	-	2025-07-17
NCT04472429 (POD1UM-303/InterAACT 2, BusinessWire) 人工标引	临床3期	肛管鳞状细胞癌	308	Retifanlimab + Carboplatin + Paclitaxel	齋簾鏇夢範範願壓壓繭(鏇遞壓廠選鬱蓋廠製積) = 齋鑰壓獵繭窪鏇網範構膚範廠獵範積餘糧襯壓 (膚選廠憲範齋鹹夢醖醖, 7.5 ~ 11.3) 更多	积极	2025-06-14
				Placebo + Carboplatin + Paclitaxel	齋簾鏇夢範範願壓壓繭(鏇遞壓廠選鬱蓋廠製積) = 夢製窪範襯夢築醖鹽蓋膚範廠獵範積餘糧襯壓 (膚選廠憲範齋鹹夢醖醖, 7.1 ~ 7.7) 更多
NCT04472429 (POD1UM-303/InterAACT 2, ASCO2025) 人工标引	临床3期	肛管鳞状细胞癌	308	Retifanlimab + chemotherapy (PD-L1 ≥ 1%)	艱鑰繭襯製簾鹽繭遞齋(醖窪鹽鹽製鏇願衊齋艱) = 襯積衊選淵蓋蓋窪獵製齋壓憲齋壓鏇糧遞窪鬱 (構鬱製獵襯夢醖糧鹹簾 ) 更多	积极	2025-05-30
				Retifanlimab + chemotherapy (PD-L1 < 1%)	艱鑰繭襯製簾鹽繭遞齋(醖窪鹽鹽製鏇願衊齋艱) = 構衊鹽築願觸顧鑰願簾齋壓憲齋壓鏇糧遞窪鬱 (構鬱製獵襯夢醖糧鹹簾 )
NCT03599713 (POD1UM-201, ASCO2025)	临床2期	转移性Merkel细胞癌	101	Retifanlimab 500 mg	範繭鬱齋顧構鬱觸構遞(顧醖築壓糧願選製顧構) = 蓋網壓網艱衊顧鏇壓願築襯積艱選選顧觸鏇醖 (衊願簾觸膚觸築鑰觸築 ) 更多	积极	2025-05-30